Nordic Capital Acquires Advanz Pharma for $846 Million

Published on: 

The acquisition of Advanz Pharma by Nordic Capital has now completed, in a deal worth $846 million.

Advanz Pharma has announced, in a June 1, 2021 press release, that its acquisition by Nordic Capital—a subsidiary of Nordic Fund X Epsilon, Cidron Aida Bidco Limited—has now completed. The deal was struck for $846 million.

“This deal is fantastic news for Advanz Pharma and our goal of becoming the go-to partner for complex medicines in Europe. Nordic Capital will be pivotal in helping the business through both its deep sector expertise and access to capital that will enable considerable investment in our organic and inorganic pipeline. This partnership will be essential in allowing us to further broaden choice for both prescribers and patients throughout the world and ensure access to the essential medicines we supply,” said Graeme Duncan, CEO of Advanz Pharma, in the press release. “This deal could not have been possible without our employees whose hard work has been instrumental in collectively contributing towards building Advanz Pharma into the strong and diverse company it is today.”

Raj Shah, partner and head of Healthcare, Nordic Capital Advisors, added, in the press release, “Advanz Pharma’s vision and regional focus fully aligns with Nordic Capital’s expertise and deep knowledge of European market sectors. We are delighted to be able to support Advanz Pharma at this exciting juncture in their journey. Nordic Capital will help fuel the company’s strategic growth and allow it to invest in future pipeline and M&A activities so that even more patients can access critical medicines now and in the future.”


Source: Advanz Pharma